Viridian Therapeutics is focused on engineering and developing potential best-in-class medicines for people living with autoimmune and rare diseases. Viridian is studying multiple candidates in clinical studies for TED.

For more information on our ongoing clinical studies for people affected by TED, please visit clinicaltrials.gov or speak with a healthcare provider.

Learn More About
Clinical Trials

View

Featured Trials

THRIVE

Active Thyroid Eye Disease

Global Phase 3 trial to evaluate the efficacy and safety of VRDN-001 in patients with active TED

THRIVE-2

Chronic Thyroid Eye Disease

Global Phase 3 trial to evaluate the efficacy and safety of VRDN-001 in patients with chronic TED

REVEAL-1

Active Thyroid Eye Disease

Global phase 3 trial to evaluate the efficacy and safety of VRDN-003 administered subcutaneously in patients with active TED.

REVEAL-2

Chronic Thyroid Eye Disease

Global phase 3 trial to evaluate the efficacy and safety of VRDN-003 administered subcutaneously in patients with chronic TED.

Clinical Trials

Featured Trials

THRIVE

THRIVE-2

REVEAL-1

REVEAL-2

Pipeline

Special Thanks to Patients